Jeffrey Johnson

907 total citations
30 papers, 404 citations indexed

About

Jeffrey Johnson is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Jeffrey Johnson has authored 30 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Jeffrey Johnson's work include CAR-T cell therapy research (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Breast Cancer Treatment Studies (4 papers). Jeffrey Johnson is often cited by papers focused on CAR-T cell therapy research (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Breast Cancer Treatment Studies (4 papers). Jeffrey Johnson collaborates with scholars based in United States, Denmark and Singapore. Jeffrey Johnson's co-authors include Xiaojiang Cui, Ying Qu, Frank G. Haluska, Armando E. Giuliano, Donna Niedzwiecki, Marcello Marelli, Michelle A. Blaskovich, April K.S. Salama, Hengyu Xu and Gary Li and has published in prestigious journals such as Blood, Oncogene and Scientific Reports.

In The Last Decade

Jeffrey Johnson

25 papers receiving 391 citations

Peers

Jeffrey Johnson
Zhenqing Feng China
Heather C. Workman United States
Kyriaki Tzogani Netherlands
Lance M. Tibbetts United States
Jane Mayotte United States
Yin Gu United States
Hsien‐Yu Tsai Taiwan
Ines De Pauw Belgium
Ludimila Cavalcante United States
Zhenqing Feng China
Jeffrey Johnson
Citations per year, relative to Jeffrey Johnson Jeffrey Johnson (= 1×) peers Zhenqing Feng

Countries citing papers authored by Jeffrey Johnson

Since Specialization
Citations

This map shows the geographic impact of Jeffrey Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Johnson more than expected).

Fields of papers citing papers by Jeffrey Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Johnson. The network helps show where Jeffrey Johnson may publish in the future.

Co-authorship network of co-authors of Jeffrey Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Johnson. A scholar is included among the top collaborators of Jeffrey Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Johnson. Jeffrey Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ryu, Jai Min, Chi Wei Mok, Antonio Toesca, et al.. (2025). Consensus Statement on Robotic Nipple Sparing Mastectomy Expert Panel. Journal of Breast Cancer. 28(3). 180–180.
2.
Sharifzadeh, Yasamin, Arkadiusz Z. Dudek, Svetomir N. Markovic, et al.. (2025). Minibeam Radiation Therapy for Recurrent Mucosal Melanoma: An Eye-Opening Response. Mayo Clinic Proceedings Innovations Quality & Outcomes. 9(4). 100640–100640.
3.
4.
Miller, James, Jeffrey Johnson, Kevin Waters, et al.. (2021). Disparities and survival in newly diagnosed gastric cancer in Hispanic patients in the United States: a propensity score matched analysis. Journal of Gastrointestinal Oncology. 12(4). 1308–1325. 8 indexed citations
5.
Johnson, Jeffrey, Paula D. Strassle, Guilherme C. de Oliveira, et al.. (2021). Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients. Breast Cancer Research and Treatment. 189(2). 509–520. 6 indexed citations
6.
7.
Crystal, Jessica S., Jeffrey Johnson, Sung‐Jin Kim, et al.. (2020). Adjuvant endocrine therapy is associated with improved overall survival in elderly hormone receptor-positive breast cancer patients. Breast Cancer Research and Treatment. 184(1). 63–74. 4 indexed citations
8.
Bloom, Matthew B., et al.. (2019). Improved prediction of HIT in the SICU using an improved model of the Warkentin 4-T system: 3-T. The American Journal of Surgery. 219(1). 54–57. 4 indexed citations
9.
Bohnert, Kathryn L., Mary K. Hastings, David R. Sinacore, et al.. (2019). Defining the Cellular Basis for Poor Muscle Performance in Diabetic Peripheral Neuropathy. Foot & Ankle Orthopaedics. 4(4). 1 indexed citations
10.
Marotta, Michael, Jeffrey Johnson, G. Thomas Budd, et al.. (2017). Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors. Scientific Reports. 7(1). 41921–41921. 25 indexed citations
11.
Qu, Ying, Bo Zhou, Wei Yang, et al.. (2016). Transcriptome and proteome characterization of surface ectoderm cells differentiated from human iPSCs. Scientific Reports. 6(1). 32007–32007. 27 indexed citations
12.
Jin, Yanli, Bangwoo Han, Ying Qu, et al.. (2016). FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance. Oncogene. 35(41). 5400–5411. 32 indexed citations
13.
Johnson, Jeffrey, Michael Choi, Farnaz Dadmanesh, et al.. (2016). FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. Oncotarget. 7(46). 75729–75738. 12 indexed citations
14.
Stenderup, Karin, Cecilia Rosada, Kurt Shanebeck, et al.. (2015). AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use—improves psoriasis in a human xenograft transplantation model. Protein Engineering Design and Selection. 28(10). 467–480. 14 indexed citations
15.
Fulton, Noreen, Jeffrey Johnson, Lawrence D. Kaplan, et al.. (2013). Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance). Blood. 122(21). 3002–3002. 2 indexed citations
16.
Gajewski, Thomas F., April K.S. Salama, Donna Niedzwiecki, et al.. (2012). Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). Journal of Translational Medicine. 10(1). 246–246. 56 indexed citations
17.
Roberts, John D., Donna Niedzwiecki, William E. Carson, et al.. (2005). Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma. Journal of Immunotherapy. 29(1). 95–101. 16 indexed citations
18.
Stock, Wendy, Jeffrey Johnson, Daohai Yu, et al.. (2005). Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.. Blood. 106(11). 1833–1833. 7 indexed citations
19.
Janss, Anna J., John T. Sladky, Jane Chatten, & Jeffrey Johnson. (1996). Opsoclonus/myoclonus: Paraneoplastic syndrome of neuroblastoma. Medical and Pediatric Oncology. 26(4). 272–279. 6 indexed citations
20.
Janss, Anna J., John T. Sladky, Jane Chatten, & Jeffrey Johnson. (1996). Opsoclonus/myoclonus: Paraneoplastic syndrome of neuroblastoma. Medical and Pediatric Oncology. 26(4). 272–279. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhenqing Feng Breakdown of academic impact, for papers by Heather C. Workman Breakdown of academic impact, for papers by Kyriaki Tzogani Breakdown of academic impact, for papers by Lance M. Tibbetts Breakdown of academic impact, for papers by Jane Mayotte Breakdown of academic impact, for papers by Yin Gu Breakdown of academic impact, for papers by Hsien‐Yu Tsai Breakdown of academic impact, for papers by Ines De Pauw Breakdown of academic impact, for papers by Ludimila Cavalcante
Rankless by CCL
2026